

Electronic Acknowledgement Receipt

EFS ID:	3379849
Application Number:	10584151
International Application Number:	
Confirmation Number:	7001
Title of Invention:	Acidic quinoline derivatives and their use for the prevention and/or treatment of hyperglycaemia-related pathologies
First Named Inventor/Applicant Name:	Gerard Moinet
Customer Number:	23599
Filer:	Csaba Henter/Pamela Richardson
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	MERCK-3186
Receipt Date:	30-MAY-2008
Filing Date:	22-JUN-2006
Time Stamp:	12:49:34
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	8469
Deposit Account	
Authorized User	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	----------------------------------	------------------	------------------

1		Reply-5-30-08.pdf	222705	yes	6
			3c108719fb795514b88689061a73ab4f561b3dda		
	Multipart Description/PDF files in .zip description				
	Document Description	Start	End		
	Amendment - After Non-Final Rejection	1	1		
	Claims	2	5		
	Applicant Arguments/Remarks Made in an Amendment	6	6		
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed	InformationDisclosureStatement-5-30-08.pdf	168383	no	4
			c06234993cacd474afbfef20745afa7e9767b0fa		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Information Disclosure Statement (IDS) Filed	PTO-1449-5-30-08.pdf	201589	no	2
			63fc025f0c27703761b14eebc3f333965c57cb25		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	Foreign Reference	WO03010146.pdf	13246262	no	283
			faed8baa32bd67711248642e2bcb41e257449da0		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
5	Foreign Reference	EP0433679A3.pdf	87786	no	3
			20e0b4c6f0523324b132533dca7140ba4b5c2793		
Warnings:					
Information:					
6	Foreign Reference	EP0398283B1.pdf	3258106	no	75
			8d99abdee921a5c1d8d679ccce14f33fb2bf5fa6		
Warnings:					
Information:					
7	Foreign Reference	FR2791263.pdf	428469	no	9
			f8aa849898e77537d1821047b75fb5d6dedb3e70		

Warnings:					
Information:					
8	Foreign Reference	WO2004007461.pdf	6619326	no	149
			ada79c1f112285872ad02591360e670642d75c94d		
Warnings:					
Information:					
9	Foreign Reference	WO2004045614.pdf	2079643	no	41
			f6d17ae4dcac690da26cdb3a5e183872c1889eaa		
Warnings:					
Information:					
10	NPL Documents	HarrisonBoydEtAl-4-Carboxymethoxy-XP001199578.pdf	334074	no	3
			a00073f77ca2b00845b387bf96e2879a4955fcd		
Warnings:					
Information:					
11	NPL Documents	SalituroEtAl-3-2-Carboxyindole-3-YLPropionic.pdf	1192071	no	9
			65d09e665131b43cc262a97c2f92d033e652b5f4		
Warnings:					
Information:					
12	NPL Documents	KotakeEtAl-XP-002294269-XanthurenicAcidXVI.pdf	48287	no	1
			230931ce46f9bbd4765ea3f824aa0030c53a9282		
Warnings:					
Information:					
13	NPL Documents	CarvalhoEtAl-RoleOfEndogenousAngiotensin.pdf	690199	no	6
			ba54961c620a5b7ba562135bd2d1data3b58a851		
Warnings:					
Information:					
14	NPL Documents	KotakeEtAl-APossibleDiabetogenicRoleForTryptophan.pdf	323631	no	4
			cbb9d83406441f5234c0348593854af2336a2b61		
Warnings:					
Information:					
15	NPL Documents	SandersEtAl-L-AminoAcidInhibitionOfEpinephrine.pdf	575792	no	10
			9cd31238529ce4e0994c84dd58e7c9874dd33d7f		
Warnings:					
Information:					
16	NPL Documents	StoneEtAl-EndogenousKynureninesAsTargets.pdf	1529544	no	12
			b30f1be824c066b578677e54ce5a5a6a932c4c26		

Warnings:					
Information:					
17	NPL Documents	EdmontEtAl-SynthesisAndEvaluationOfQuinoline.pdf	262548 41aba6ecc30b69bfafe04b5cc3231ae8b db679b7	no	4
Warnings:					
Information:					
18	NPL Documents	Nicolaus-SymbioticApproachToDrugDesign.pdf	827554 3710ebf2aac71efa4a53b1bad52c0198 740dedf	no	14
Warnings:					
Information:					
19	Fee Worksheet (PTO-06)	fee-info.pdf	8250 f0595e8080bf93324bea6be97c0194a1 05c06d37	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			32104219		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					